GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

gimsilumab   Click here for help

GtoPdb Ligand ID: 9624

Synonyms: MORAb-022
Immunopharmacology Ligand
Compound class: Antibody
Comment: Gimsilumab (MORAb-022) is an investigational, fully human IgG1 monoclonal antibody being evaluated for its potential in the treatment of multiple inflammatory diseases and cancer. It targets granulocyte-macrophage colony stimulating factor (GM-CSF, CSF2), a growth factor involved in autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and asthma. In the cancer setting, MORAb-022-mediated blocking of CSF2 produces a pro-immunity microenvironment that leads to tumour tissue death in preclinical studies. Peptide sequences (from the WHO INN submission for gimsilumab) match sequences 8 and 12 from Morphotek Inc. patent WO2007092939 [1], and these sequences belong to monoclonal antibody clone G9 specified in the patent.
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
10534 gimsilumab
Synonyms Click here for help
MORAb-022
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 756
Other databases
GtoPdb PubChem SID 340590254
Search PubMed clinical trials gimsilumab
Search PubMed titles gimsilumab
Search PubMed titles/abstracts gimsilumab